首页> 外文期刊>International Journal of Reproduction, Contraception, Obstetrics and Gynecology >A comparative study of efficacy, safety and compliance of oral iron versus intravenous iron sucrose in treatment of iron deficiency anaemia of pregnancy
【24h】

A comparative study of efficacy, safety and compliance of oral iron versus intravenous iron sucrose in treatment of iron deficiency anaemia of pregnancy

机译:口服铸铁效力,安全性和依然血管铁蔗糖治疗怀孕缺氧贫血的疗效,安全性和依从性的比较研究

获取原文
           

摘要

Background: Iron deficiency anemia is the most common form of anemia and nutritional disorder worldwide. Oral iron therapy and blood transfusion has many drawbacks like noncompliance and risk of transmittable infections and transfusion reaction. The modern alternative therapy is treatment with intravenous iron. Present study compares the efficacy, safety and tolerability between intravenous iron sucrose and oral iron in iron deficiency anemia during 20-36 weeks of pregnancy. Methods: It was a randomized controlled study between December 2017 to September 2019. 200 patients attending antenatal OPD in Al Ameen Medical College, with haemoglobin levels between 7-9.9 gm/dl and serum ferritin of 15 ng/ml were enrolled. In intravenous group, 200 mg iron sucrose in 100ml normal saline was infused alternate day till the required dose was met. The oral group received 200 mg of oral iron ascorbate along with folic acid 1.5 mg per day for 6 weeks. Treatment efficacy was assessed by Hb and serum ferritin after 3 and 6 weeks. Results: Out of 200 patients, an increase in Hb was observed in both groups, rising from 9.7 g/dl to 10.3 g/dl and 10.9 g/dl after 3 weeks and 6 weeks respectively in oral group and from 8.6 g/dl to 9.8 g/dl and 10.8 g/dl after 3 weeks and 6 weeks respectively in intravenous group. Similar results were seen in ferritin levels. Rise in Hb and ferritin levels were greater in intravenous group than in oral group. Conclusions: Intravenous iron sucrose appears to be a better treatment option in comparison with oral iron, without serious side effects, better compliance and improved efficacy in correction of anaemia of pregnancy.
机译:背景:缺铁性贫血是全球最常见的贫血和营养疾病形式。口服铁疗法和输血具有许多缺点,如不合规和可传递感染和输血反应的风险。现代替代治疗是用静脉内熨斗治疗。目前的研究比较了在妊娠20-36周内静脉内铁蔗糖和口服铁之间的疗效,安全性和耐受性。方法:2017年12月至2019年12月之间是一项随机对照研究。2009年9月,参加Al Ameen医学院的产蛋opd,血红蛋白水平在7-9.9gm / dl和<15 ng / ml的血清铁蛋白的血清水平进行注册。在静脉内群中,100ml甘露出盐的200mg铁蔗糖注入交替的一天,直至满足所需的剂量。口腔基团接受200mg的口服铁抗坏血酸和叶酸每天1.5mg持续6周。在3和6周后,通过Hb和血清铁蛋白评估治疗疗效。结果:在200名患者中,两组中观察到Hb的增加,从9.7g / d1增加至10.3g / dl和10.9g / dl,分别在口服组和8.6g / d1中升至6周。 9.8g / dl分别在静脉内群体3周和6周后的9.8g / dl和10.8g / dl。在铁蛋白水平中可以看到类似的结果。静脉内群体的Hb和铁蛋白水平升高于口腔群体。结论:与口服铁相比,静脉注射铁蔗糖似乎是更好的治疗选择,没有严重的副作用,更好的依从性和改善妊娠期贫血的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号